| P2093 | author name string | Karen A Tourian | |
| | James M Ferguson | |
| | Gregory R Rosas | |
| P2860 | cites work | An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder | Q28243389 |
| | The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) | Q29547223 |
| | A New Depression Scale Designed to be Sensitive to Change | Q29614720 |
| | An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. | Q30448309 |
| | Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose | Q34347727 |
| | Treatment non-adherence in affective disorders. | Q34592227 |
| | What Clinicians Should Know About the QT Interval | Q35112554 |
| | How to correct the QT interval for the effects of heart rate in clinical studies | Q35128726 |
| | Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo | Q44032099 |
| | Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial | Q45181161 |
| | Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial | Q46428909 |
| | A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder | Q46965384 |
| | A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. | Q48469062 |
| | Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. | Q50532923 |
| | Antidepressant-Associated Mania and Psychosis Resulting in Psychiatric Admissions | Q56209637 |
| | SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants | Q64116647 |
| | Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder | Q94700793 |
| P433 | issue | 3 | |
| P304 | page(s) | 121-130 | |
| P577 | publication date | 2012-08-10 | |
| P1433 | published in | C N S Spectrums | Q15750260 |
| P1476 | title | High-dose desvenlafaxine in outpatients with major depressive disorder | |
| P478 | volume | 17 | |